Olsalazine Sodium (CAS 6054-98-4)
See product citations (2)
QUICK LINKS
Olsalazine Sodium is a compound utilized primarily in research concerning intestinal inflammation and colon health. It consists of two salicylate moieties linked by an azo bond, a structure that is of particular interest in the study of azo-reduction pathways within the intestinal microbiota. Research involving Olsalazine Sodium focuses on its role in modulating inflammatory responses and its interaction with the colonic environment. The compound′s breakdown by colonic bacteria releases bioactive metabolites, which are then investigated for their effects on various cellular pathways related to inflammation and cellular proliferation. Additionally, Olsalazine Sodium serves as a model compound for studying the impact of azo compounds on the gastrointestinal system. The research outcomes aid in understanding the complex interactions between chemical compounds and the intestinal microbiome, as well as the broader implications for intestinal health.
Olsalazine Sodium (CAS 6054-98-4) References
- Determination of olsalazine sodium in pharmaceuticals by differential pulse voltammetry. | Uslu, B., et al. 2001. Pharmazie. 56: 629-32. PMID: 11534339
- Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. | Knoll, U., et al. 2002. J Vet Pharmacol Ther. 25: 135-43. PMID: 12000534
- 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. | Van Staa, TP., et al. 2004. Gastroenterology. 126: 1733-9. PMID: 15188168
- Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. | Rubin, DT., et al. 2006. Clin Gastroenterol Hepatol. 4: 1346-50. PMID: 17059900
- Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. | Wadworth, AN. and Fitton, A. 1991. Drugs. 41: 647-64. PMID: 1711964
- Medication non-adherence is associated with increased medical health care costs. | Kane, S. and Shaya, F. 2008. Dig Dis Sci. 53: 1020-4. PMID: 17934828
- Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. | Banda, J., et al. 2016. J Chromatogr B Analyt Technol Biomed Life Sci. 1008: 1-10. PMID: 26606108
- Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. | Willoughby, CP., et al. 1988. Scand J Gastroenterol Suppl. 148: 40-4. PMID: 2906476
- Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity. | Niu, Y., et al. 2017. J Pharmacol Sci. 135: 114-120. PMID: 29132796
- Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals. | Niu, Y., et al. 2020. Biol Pharm Bull. 43: 1653-1659. PMID: 32863294
- Pericarditis as the initial manifestation of inflammatory bowel disease. | Sarrouj, BJ., et al. 1994. Chest. 106: 1911-2. PMID: 7988229
- Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. | Ferry, GD., et al. 1993. J Pediatr Gastroenterol Nutr. 17: 32-8. PMID: 8102399
- Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon. | DiGiovanni, RL., et al. 1995. J Am Osteopath Assoc. 95: 572. PMID: 8557544
- Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. | Kruis, W., et al. 1998. Aliment Pharmacol Ther. 12: 707-15. PMID: 9726382
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Olsalazine Sodium, 25 mg | sc-205776 | 25 mg | $87.00 | |||
Olsalazine Sodium, 100 mg | sc-205776A | 100 mg | $203.00 |